Characteristics of matched patients with and without SLE experiencing COVID-19-SLE from March to November 2020 in France
| COVID-19-AOF | SLE non-COVID-19 | Standardised differences† | ||
| SLE | Non-SLE | |||
| n=190 | n=908 | n=170 | ||
| Age, years, median (Q1–Q3)‡ | 65 (54–76) | 66 (55–77) | 63 (52–75) | −0.0630 |
| Male sex, n (%)‡ | 48 (25.3) | 235 (25.8) | 37 (21.8) | 0.0142 |
| Arterial hypertension, n (%)‡ | 137 (72.1) | 656 (72.3) | 124 (72.9) | −0.0032 |
| Cardiovascular history, n (%)‡ | 81 (42.6) | 380 (41.9) | 69 (40.6) | 0.0158 |
| Chronic kidney disease, n (%)‡ | 75 (39.5) | 341 (37.6) | 66 (38.8) | 0.0394 |
| Obesity, n (%)‡ | 68 (35.8) | 318 (35.0) | 56 (32.9) | 0.0160 |
| Chronic pulmonary disease, n (%)‡ | 53 (27.9) | 253 (27.9) | 40 (23.5) | 0.0007 |
| Diabetes mellitus, n (%)‡ | 51 (26.8) | 254 (27.9) | 42 (24.7) | −0.0254 |
| ICU admission, n (%) | 82 (43.2) | 391 (43.1) | ||
| SAPS II at ICU admission, median (Q1–Q3)* | 36 (27–53) | 37 (27–50) | 0.0028 | |
| Invasive mechanical ventilation, n (%) | 36 (18.9) | 169 (18.6) | 0.0086 | |
| Renal replacement therapy for AKI, n (%) | 13 (6.8) | 61 (6.7) | 0.0049 | |
| Use of pressor amines, n (%) | 31 (16.3) | 147 (16.2) | 0.0034 | |
Characteristics of a matched SLE population admitted to French hospitals without any evidence of COVID-19 during the same period are also presented for information.
*SAPS II is only available for ICU-admitted patients.
†Standardised differences are given for significance of the difference between the first two groups.
‡Matching variables.
AKI, acute kidney injury; AOF, associated organ failure; ICU, intensive care unit; Q1, first quartile; Q3, third quartile; SAPS II, Simplified Acute Physiology Score; SLE, systemic lupus erythematosus.